FDA Inspection 1132014 — Amarin Pharma, Inc.
The FDA completed an inspection of Amarin Pharma, Inc. on Oct 6, 2020 in Bridgewater, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Oct 6, 2020
- Fiscal Year
- 2021
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Bridgewater, NJ (United States)
Additional details
Postmarket Adverse Drug Experience (PADE)